Workflow
润都股份(002923) - 2021 Q1 - 季度财报
Rundu PharmaRundu Pharma(SZ:002923)2021-04-22 16:00

Revenue and Profit - The company's revenue for Q1 2021 was ¥324,097,123.51, representing a 2.00% increase compared to ¥317,755,476.17 in the same period last year[7] - Net profit attributable to shareholders was ¥35,043,698.73, up 9.61% from ¥31,971,613.75 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥32,378,567.30, reflecting a 15.51% increase from ¥28,031,016.40 in the previous year[7] - Basic earnings per share for the period were ¥0.19, a 5.56% increase from ¥0.18 in the same period last year[7] - The company reported a total comprehensive income of CNY 35,043,698.73 for Q1 2021, compared to CNY 31,971,613.75 in the previous period[45] - The net profit for the first quarter of 2021 was CNY 38,288,688.09, an increase from CNY 37,716,011.97 in the same period last year, representing a growth of approximately 1.52%[48] - The total profit for the quarter reached CNY 44,661,321.46, up from CNY 41,326,202.35, reflecting a growth of approximately 8.00%[48] Cash Flow - The net cash flow from operating activities was -¥22,262,319.72, a significant decrease of 139.48% compared to ¥56,392,334.38 in the same period last year[7] - Cash flow from operating activities showed a net outflow of CNY -22,262,319.72, a significant decrease compared to a net inflow of CNY 56,392,334.38 in the previous year[52] - The company reported cash inflow from operating activities of CNY 239,807,630.11, down from CNY 275,882,551.27 in the previous year, indicating a decline of approximately 13.06%[52] - The company's operating cash outflow totaled CNY 262,069,949.83, compared to CNY 219,490,216.89 in the previous year, indicating an increase of approximately 19.30%[52] - The company reported a net cash outflow from financing activities of -2,512,121.27 CNY in Q1 2021, compared to a net inflow of 53,029,058.49 CNY in Q1 2020[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,625,348,353.61, an increase of 7.37% from ¥1,513,772,150.91 at the end of the previous year[7] - The net assets attributable to shareholders were ¥1,075,360,811.10, up 3.58% from ¥1,038,233,649.90 at the end of the previous year[7] - Total liabilities decreased to CNY 549,987,542.51 from CNY 475,538,501.01, a reduction of about 15.59%[36] - The company's equity increased to CNY 1,075,360,811.10 from CNY 1,038,233,649.90, showing a growth of approximately 3.58%[37] - Total liabilities decreased to CNY 307,749,914.22 from CNY 332,328,549.23[43] Investments and Expenses - The company received government subsidies amounting to ¥3,059,777.30 during the reporting period[8] - Research and development expenses for Q1 2021 were CNY 18,827,629.40, down from CNY 24,089,902.58 in the previous period, indicating a reduction of approximately 21.7%[43] - Sales expenses decreased to CNY 118,782,245.60 from CNY 121,338,018.14, a decline of about 2.1%[43] - The company reported an 84.04% decrease in investment income to ¥165,011.74, mainly due to reduced wealth management returns[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,846[11] - The total amount of funds raised from the public offering was ¥425,250,000.00, with a net amount of ¥345,610,300.00 after deducting issuance costs[24] Other Financial Metrics - The weighted average return on equity remained stable at 3.33%[7] - The company has a remaining balance of raised funds of ¥60,921,110.25, including interest income and wealth management returns[24] - The solid preparation workshop renovation project has achieved an investment progress of 72.89% as of March 31, 2021[24]